October 30, 2014
BOSTON — At the Cardiometabolic Health Congress, Keith C. Ferdinand, MD, FACC, professor of clinical medicine at Tulane University School of Medicine in New Orleans, outlines recent trial data and FDA updates related to CV and diabetes care.
During a session, Ferdinand discussed a trial that assessed the impact of the GLP-1 agonist dulaglutide on BP and heart rate in a cohort of 755 patients. Ferdinand, who was the principal investigator for the trial, noted a small increase in heart rate with dulaglutide 1.5 mg compared with placebo, but similar results between placebo and dulaglutide 0.75 mg. Patients who received the 1.5 mg dose also exhibited a significant decrease in BP during a 24-hour period. He noted that, while the trial did not assess CV outcomes, results suggest that GLP-1 agonists may aid in BP control, although long-term outcome trials should be performed to determine whether the observed heart rate increase is potentially problematic.